Feasibility of single-stage direct-to-implant subpectoral breast reconstruction following neoadjuvant chemotherapy for locally advanced breast cancer

局部晚期乳腺癌新辅助化疗后单阶段直接植入式胸大肌下乳房重建术的可行性研究

阅读:1

Abstract

Breast reconstruction is increasingly requested in breast cancer surgery, particularly among young women. However, the criteria for its feasibility need to be more clearly defined. This study aimed to compare the surgical safety and long-term oncologic survival outcomes between immediate breast reconstruction (IBR) and conventional mastectomy (CMx) and to determine the main factors affecting recurrence, considering tumor-specific features. The study analyzed 297 patients with locally advanced breast cancer (stage IIB-IIIC and/or axilla positive) who underwent CMx or IBR between January 2015 and December 2021 at Istanbul University, Oncology Institute, and mainly investigated the outcomes of both surgical interventions regarding recurrence and survival rates. The study examined 132 patients who underwent the CMx and 165 with the IBR procedure. Median follow-up was 60.2 months (range, 12-107). On average, younger patients (43.36 vs 50.42, P < .001) and patients with relatively early-stage tumors (P = .007, for cT and P = .004, for cN) underwent the IBR procedure more often compared with CMx. There was no difference between the 2 groups regarding other tumor-specific characteristics, receptor profiles, regimens of neoadjuvant chemotherapy, response to neoadjuvant chemotherapy, and adjuvant therapies (P > .05 for each comparison). The definitive pT stage had the highest risk for local recurrence, with a 3.2-fold increased risk independent of the type of surgery performed (P < .001, 3.22 (1.56-6.66)). However, no difference was between the IBR and CMx groups regarding local recurrence (84.8% vs 85.6%), distant metastasis (81.2% vs 79.5%), free survival rates, and overall survival (94.95 months vs 93.47 months, P = .916). Immediate breast reconstruction is a safe and feasible approach in patients with locally advanced breast cancer receiving neoadjuvant therapy compared to CMx alone, as it does not affect recurrence rates and survival.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。